CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 908 enrolled
Drug / intervention
13-valent pneumococcal conjugate vaccine +13 morebiological
Likely dose
Paracetamol 15mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01392378
NCT01392378Phase 4Completed

A Phase 4, Randomized, Open-Label Trial To Assess The Impact Of Prophylactic Antipyretic Medication On The Immunogenicity Of 13-Valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations In Healthy Infants

Pfizer·interventional·Posted Jul 12, 2011·Updated Feb 26, 2014

In Brief

A Phase 4 clinical trial evaluating 13-valent pneumococcal conjugate vaccine, INFANRIX hexa, and 2 other interventions for Pneumococcal Vaccines. Completed, enrolled 908 participants across 14 sites.

Detailed Summary

The purposes of this study are assess the immunological response (measure the amount of antibodies, i.e. proteins that fight off germs) produced by children after they have been given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months of age when medications to prevent fever are given on the same day as the vaccination. Also to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who receive medications to prevent fever on the day of vaccination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 12, 2011
Enrollment StartAug 1, 2011
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.0 years ago

Interventions

13-valent pneumococcal conjugate vaccinebiological

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

INFANRIX hexabiological

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Paracetamoldrug

Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

13-valent pneumococcal conjugate vaccinebiological

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

INFANRIX hexabiological

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Ibuprofendrug

Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.

13-valent pneumococcal conjugate vaccinebiological

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

INFANRIX hexabiological

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Paracetamoldrug

Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

13-valent pneumococcal conjugate vaccinebiological

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

INFANRIX hexabiological

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

Ibuprofendrug

Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.

13-valent pneumococcal conjugate vaccinebiological

13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.

INFANRIX hexabiological

INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.